Review Article

Natural Killer T (NKT) Cells and Periodontitis: Potential Regulatory Role of NKT10 Cells

Samanta Melgar-Rodríguez,1,2 Emilio A. Cafferata,1,3 Nicolás I. Díaz,1 Miguel A. Peña,1 Luis González-Osuna,1 Carolina Rojas,1 Alfredo Sierra-Cristancho,1,4 Angélica M. Cárdenas,1,5 Jaime Díaz-Zúñiga,1,2 and Rolando Vernal1,2

1Periodontal Biology Laboratory, Faculty of Dentistry, Universidad de Chile, Santiago, Chile
2Department of Conservative Dentistry, Faculty of Dentistry, Universidad de Chile, Santiago, Chile
3Department of Periodontology, School of Dentistry, Universidad Científica del Sur, Lima, Peru
4Faculty of Dentistry, Universidad Andres Bello, Santiago, Chile
5Health Sciences Division, Faculty of Dentistry, Universidad Santo Tomás, Bucaramanga, Colombia

Correspondence should be addressed to Samanta Melgar-Rodríguez; smelgar@odontologia.uchile.cl and Rolando Vernal; rvernal@uchile.cl

Received 23 February 2021; Accepted 24 August 2021; Published 21 September 2021

Academic Editor: Patrick R. Schmidlin

Copyright © 2021 Samanta Melgar-Rodríguez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Natural killer T (NKT) cells constitute a unique subset of T lymphocytes characterized by specifically interacting with antigenic glycolipids conjugated to the CD1d receptor on antigen-presenting cells. Functionally, NKT cells are capable of performing either effector or suppressor immune responses, depending on their production of proinflammatory or anti-inflammatory cytokines, respectively. Effector NKT cells are subdivided into three subsets, termed NKT1, NKT2, and NKT17, based on the cytokines they produce and their similarity to the cytokine profile produced by Th1, Th2, and Th17 lymphocytes, respectively. Recently, a new subgroup of NKT cells termed NKT10 has been described, which cooperates and interacts with other immune cells to promote immunoregulatory responses. Although the tissue-specific functions of NKT cells have not been fully elucidated, their activity has been associated with the pathogenesis of different inflammatory diseases with immunopathogenic similarities to periodontitis, including osteolytic pathologies such as rheumatoid arthritis and osteoporosis. In the present review, we revise and discuss the pathogenic characteristics of NKT cells in these diseases and their role in the pathogenesis of periodontitis; particularly, we analyze the potential regulatory role of the IL-10-producing NKT10 cells.

1. Introduction

The first evidence of the existence of Natural Killer T (NKT) cells appeared in 1987 [1–3]. Specifically, when a particular population of αβT lymphocytes, expressing the Vβ8 chain of the T-cell receptor (TCR) more frequently than in conventional T lymphocytes and lacking the expression of CD4 and CD8 markers, was described [1–3]. However, it was not until 1995 that NKT cells were formally described as a subset of T lymphocytes with characteristics similar to Natural Killer (NK) cells, characterized by the expression of the NK marker NK1.1 [4–6]. From these studies, the interest in NKT cells has gradually increased due to their possible role in the pathogenesis of several inflammatory and autoimmune diseases, in particular when a subpopulation of NKT cells with promising immunoregulatory functions was reported [2, 3, 7].

NKT cells were preliminarily characterized by expressing an invariant chain of the TCR: in humans, the Vα24/Jα18 associated with the Vβ11 chain, and in mice, the Vα14/Jα18 chain associated with the Vβ2, Vβ8, or Vβ7 chain, together with the memory T lymphocyte marker CD45RO [8, 9]. Overall, NKT cells have demonstrated an important capacity to produce a diverse milieu of proinflammatory and anti-
inflammatory cytokines, as well as costimulatory molecules, to promote cell activation [8, 9]. In relation to antigen recognition, NKT cells are specifically sensitive to glycolipid antigens conjugated to a specific receptor termed CD1d, a class Ii monomorphic molecule expressed by antigen-presenting cells (APCs), independent from the major histocompatibility complex (MHC) molecules [5, 10, 11]. Thus, CD1d, characterized by the expression of three extracellular domains (α1, α2, and α3) and formation of a heterodimer with β2-microglobulin, acts as a non-classical MHC I molecule [2, 11]. Indeed, the CD1d/β2-microglobulin complex conjugates with glycolipid antigens that, together with costimulatory molecules, promote the activation, proliferation, and selective differentiation of NKT cells [12] (Figure 1).

The NKT cell number and function are disturbed in a variety of autoimmune and inflammatory diseases; however, it still remains unclear whether these changes are directly related to the etiopathogenesis of these diseases [13]. Certainly, NKT cell functional deficiency has been proved to increase the severity in multiple mouse models for autoimmunity; however, in some models, NKT cell deficiency had no effect or even ameliorated disease, suggesting a complex relationship between autoimmunity and NKT cells [13, 14]. In humans, IFN-γ and IL-17-producing NKT cells have been identified in affected tissues in some inflammatory conditions [15–17], suggesting that the pathogenic role of NKT cells varies depending on the functional NKT subset involved.

### 2. Maturation and Differentiation of NKT Cells

In mice, NKT cells can be divided into two main groups, type I and type II NKT cells [11, 18]. Type I NKT cells express an invariant TCR α-chain associated with a TCR β-chain, the reason they are also called invariant NKT (iNKT) cells [11]. Otherwise, type II NKT cells express a diverse repertoire of TCRs similar to conventional T lymphocytes, the reason they are called diverse NKT (dNKT) cells [11, 13]. Both types of NKT cells recognize glycolipid antigens conjugated to CD1d; however, after activation, iNKT cells can display either proinflammatory or anti-inflammatory activities, while dNKT cells perform mainly anti-inflammatory functions [13, 18].

Until acquiring their final functional phenotype, mice NKT cells go through four well-defined maturation stages (stages S0 to S3), characterized by the expression of specific surface markers, a process called linear maturation [19, 20]. On the basis of this linear maturation model, NKT cells progress from an immature stage S0 as CD24⁺CD44⁻NK1.1⁻ cells, through stages S1 and S2 as CD24⁺CD44⁺NK1.1⁻ and CD24⁺CD44⁺NK1.1⁻ cells, respectively, to reach the final maturation phenotype during the stage S3 as CD24⁺CD44⁺NK1.1⁺ cells [19, 20] (Figure 2(a)).

In addition, mice NKT cells have been divided into three functional subsets, termed NKT1, NKT2, and NKT17 cells, based on the transcription factors and surface markers they express and the cytokines they produce [19, 20]. In this context, the progenitor NKT0 CD24⁺CD44⁻NK1.1⁻ cells express the EGR2 transcription factor and, after antigenic recognition and activation of the PLZF transcription factor, they differentiate into NKT1, NKT2, or NKT17 cells [9, 20–22] (Figure 2(b)). Once activated, NKT1 cells present the phenotype markers PLZF⁺HeterogeneousCD122⁻IL17RB⁺ and produce IFN-γ and low levels of IL-4, being the only NKT subset that expresses proteins characteristic of NK cells: NK1.1, NKG2D, and Nkp46 [9, 20–22]. Otherwise, NKT2 cells have the phenotype PLZF⁺highGATA3⁺CD4⁺CD27⁺IL17RB⁺ and produce increased levels of IL-4, and NKT17 cells have the phenotype PLZF⁺memRORγ⁺CD4⁺CD27⁻IL17RB⁺ and produce high levels of IL-17A [9, 20–22]. Recently, it was established that the activation of the Hivep3 transcription factor in early precursors regulates the post-selection proliferative burst and differentiation of NKT cells and that the upregulation of FcγR1y and SerpinB1 are involved in the selective generation of NKT1 and NKT17 cells, respectively [23, 24]. According to the linear differentiation model, only NKT1 cells go through all stages, S0 to S3, of the linear maturation model, unlike NKT2 and NKT17 cells that acquire their functional maturation in stage S2 [20]. In summary, IFN-γ-producing NKT1 cells, IL-4-producing NKT2 cells, and IL-17A-producing NKT17 cells are considered terminally differentiated cells, lacking the ability to transdifferentiate into another effector NKT phenotype [22, 25].

However, in the case of humans, the differentiation of the NKT subsets has not been fully described. In peripheral blood, two subpopulations of NKT cells have been described, the Va24 CD4⁺CD8⁻ and Va24 CD4⁺ NKT cells, which represent functionally different lineages that express different pattern of cytokines, chemokine receptors, and membrane integrins [26]. In particular, CD4⁺CD8⁻ NKT cells produce high levels of IFN-γ and express surface markers of the NK lineage, while CD4⁺ NKT cells produce high levels of IL-4 and IL-13, in a similar way to NK1 and NK2 cell subsets, respectively [26].

### 3. Nature of the Glycolipids Binding to CD1d

The glycolipids binding to CD1d are oligosaccharide structures bound to lipidic residues, which can have a microbial origin (natural glycolipids) or can be artificially generated (synthetic glycolipids) to experimentally induce its development and immune activity [27–29]. In bacteria, the molecular nature of immunogenic glycolipids is diverse and includes α-galactosylsialic acid glycolipid, expressed by Borrelia burgdorferi, lipophosphoglycan, expressed Leishmania donovani, α-glucosylsialic acid glycolipid, expressed Streptococcus pneumoniae, α-glucuronosylceramide and α-galacturonosylceramide, expressed by Sphingomonas species, and α-glucoside, expressed by Helicobacter pylori [30–34]. When these glycolipids interact with the APCs, their cellular internalization is dependent on the recognition by the low-intensity lipoprotein receptor (LDLR) as well as their interaction with the scavenger receptor (SR) type A (SRA), SRB1, and CD36, leading to the CD1d-glycolipid conjugation and the activation of the NF-κB and NF-AT signaling pathways, required for the subsequent induction of NKT cells [35, 36]. During the glycolipid presentation to the NKT cells, the coupling of the CD1d-glycolipid complex with the TCR results of the high-affinity interaction between the α-chain of the TCR with the sugar ring of the glycolipid and the stabilizing
interaction of the β-chain of the TCR with CD1d, triggering the NKT cell activation [37].

In an experimental manner, human and mice-derived NKT cells can also be activated with a synthetic glycolipid called α-galactosylceramide (α-GalCer) [11, 38]. In this case, the CDR1α and CDR3α complementarity regions of the TCR interact with α-GalCer, while CDR2β interacts with CD1d [39]. The α-GalCer molecule derives from the marine sponge Agelas mauritanius and is defined by the presence of anomeric glycosidic bonds with galactose residues attached to the base of sphingosine [11, 38]. Moreover, for experimental purposes, an analog of α-GalCer was recently developed, known as KRN7000 [11]. When human or murine NKT cells are stimulated with α-GalCer or KRN7000, they activate very efficiently due to their high affinity to CD1d [40, 41]. Indeed, they are capable of activating both progenitor NKT cells and mature NKT cells, leading to the production of high levels of cytokines [38, 42, 43].

4. Anatomical Distribution of NKT Cells

Effector NKT1, NKT2, and NKT17 cells are distributed differently among the distinct lymphoid organs and have particular migratory patterns associated with their maturation [19]. In the mouse’s thymus, progenitor NKT0 cells are located in the thymic cortex [8, 19]. While 70% of NKT1 and NKT17 cells reside in the thymic medulla and 30% in the cortex, 90% of NKT2 cells are located in the medulla [8, 19, 44]. During the maturation process, NKT0 cells migrate from the thymic cortex towards the medulla to acquire the phenotype NKT1, NKT2, or NKT17; otherwise, NKT1 and NKT17 cells return to the cortex, and NKT2 cells remain in the thymic medulla after maturing [16, 19] (Figure 3). Currently, the cause and mechanism involved in the return of NKT1 and NKT17 cells from the medulla towards the thymic cortex have not been clearly defined, neither why NKT2 cells do not perform this migration and remain in the thymic medulla [16, 19, 44].

The differential distribution of the NKT cell subsets in the thymus and their migration towards the peripheral tissues seems to be dependent on the chemokine receptors that they express. Indeed, the retention of mature NKT cells in the thymic medulla is associated with the surface expression of the chemokine receptor CXCR3, which interacts with its specific ligand CXCL10, expressed by medullary thymic epithelial cells (mTECs) [45, 46]. After activation and under
inflammatory conditions, the IFN-γ production by mature CXCR3+ NKT cells seems to downregulate the CXCL10 expression by mTECs, which would release the CXCL10-CXCL11 interaction and lead to the increased production of CXCL9, CXCL10, and CXCL11 in compartments such as the endothelium, favoring their migration towards peripheral tissues [45, 46].

Besides, mTECs express lymphocytoxin-β receptor (LTβR), which is essential in the regulation of the mTEC heterogeneity as an intrathymic mechanism that determines the development and function of NKT cells and their selective migration towards peripheral tissues [47].

Three distinct mTEC subsets have been described, which enable the thymus to differentially control NKT sublineages [47]. In this context, mTEC expression of LTβR controls the development of thymic tuft cells, which determines the development of NKT2 cells via IL-25, while LTβR controls CD104+CCL21+ mTECs that are capable of IL-15-transpresentation for the determination of the NKT1 and NKT17 cell development [47].

The CD28 co-stimulation has also been involved in the maturation, activation, and proliferation processes of thymus resident NKT cells [48]. In fact, blocking CD28 signaling in stage S3 NKT cells diminishes their proliferative
Importantly, PLZF is upregulated in undivided NKT cells despite the blockade of CD28, suggesting that PLZF expression is TCR-dependent and CD28-independent [48, 49]. Thus, TCR signaling induces PLZF upregulation in a process prior to cell proliferation, and the absence of CD28 signaling maintains NKT cells in a non-dividing state, which causes an increased PLZF expression when CD28 is blocked [48, 49].

In the mice spleen, NKT1 cells are located in the red pulp and NKT2 cells are located in the white pulp [8, 19]. In mice lymph nodes, NKT1 cells are mainly located in the distribution zones of both T lymphocytes and B lymphocytes, while NKT2 cells are preferentially located next to the T lymphocytes [16, 19, 44]. Similarly, NKT17 cells are located in the sub-capsular area in a comparable way to Th17 lymphocytes [21]. Recently, it has been established that the liver contains a high number of NKT1 cells and a low number of NKT2 and NKT17 cells [22], which has been ratified experimentally after the administration of α-GalCer [19, 22]. Indeed, intravenous administration of α-GalCer induced a high production of IL-4 and IFN-γ in NKT1 cells located in the splenic red pulp [19, 22]. Conversely, oral administration of α-GalCer induced the production of IL-4 but not IFN-γ in NKT2 cells located in mesenteric lymph nodes, which favored the paracrine activation of infiltrating T lymphocytes without systemic effects [19, 44]. Thus, the topographic tissue distribution of mice NKT effector cells in different immune organs could be associated with their functional potential, particularly with the local or systemic production of IL-4 and IFN-γ [19, 44]. In contrast, the distribution of NKT effector cell subsets in humans has not been described in detail yet.

5. NKT Cells and Activation of T Lymphocytes

Murine and human effector NKT cells produce high levels of cytokines immediately after being stimulated [11, 50]. This ability to rapidly produce cytokines favors the activation of other immune cell types, such as antigen-presenting cells, NK cells, B lymphocytes, CD4^+ helper T lymphocytes, and CD8^+ cytotoxic T lymphocytes, a process termed transactivation [11, 50] (Figure 4).

The transactivation of T helper lymphocytes depends on the solubility of the antigenic glycolipid that stimulates the NKT cells [11, 50]. Structural changes that increase the hydrophobicity of antigenic glycolipids favor the selective polarization of T helper lymphocytes towards the Th1 phenotype, and thus, a proinflammatory response [11]. In contrast, antigenic glycolipids with greater solubility in aqueous environments favor the differentiation and anti-inflammatory activity of Th2 lymphocytes [11]. In this context, the induction of a Th1 lymphocyte response is established when APCs internalize the antigenic glycolipid, to be conjugated to a CD1d molecule, within endosomal compartments in a hydrophobic environment and a low pH-dependent manner [11, 51]. In this way, the glycolipid/CD1d complex presentation is linked to membrane microdomains of endosomal origin, called lipid rafts [11]. In contrast, hydrophilic glycolipids promote a Th2-type anti-inflammatory response by directly associating with CD1d molecules in an endosome-independent manner [11]. Together, it is proposed that the solubility of the antigenic glycolipids determines the mechanism of interaction with the CD1d molecule and, thus, the activation of NKT cells and Th1/Th2 transactivation [11, 52].
In this sense, the activation of NKT1 cells with hydrophobic glycolipids would favor the rapid production of IFN-γ and the consequent transactivation of Th1 lymphocytes, while the activation of NKT2 cells with hydrophilic glycolipids would favor the rapid production of IL-4 and the consequent transactivation of Th2 lymphocytes [7, 11, 51, 52]. In this context, the particular condition dependent on the solubility of antigenic glycolipids that determine the activation of NKT17 cells and potential transactivation of Th17 lymphocytes has not been studied in detail.

The functional association between NKT and T-cell subsets could also be transferred to the innate lymphoid cells (ILCs), since the transcription factors and cytokines expressed by the distinct ILC subsets are also overlapping with those expressed by NKT1, NKT2, and NKT17 cells [53]. Indeed, ILC1s express the transcription factor T-bet and produce high levels of IFN-γ, similar to NKT1 cells, ILC2 cells express GATA-3 and produce IL-4 and IL-5, similarly to NKT2 cells, and ILC3 cells express RORγT and produce high levels of IL-17A and IL-22, similar to NKT17 cells [53–55]. Thus, ILCs and NKT cells could play a fundamental collaborative role in the maintenance of immune homeostasis and could promote a phenotype-specific NKT/T-cell/ILC transactivation in different disease conditions [53, 54]. In this context, the NKT1/Th1/ILC1, NKT2/Th2/ILC2, and NKT17/Th17/ILC3 responses could be coordinately deployed and together be responsible for the pathogenic changes in some diseases.

### 6. Pathologic Role of NKT1, NKT2, and NKT17 Cells

NKT cells have been associated with the pathogenesis of several diseases with diverse etiologies. In these pathological conditions, both pathological and protective NKT activities have been reported, depending on the type of pathology, its severity, the involved NKT subset, the time of exposure to antigens, and the methodology used to analyze the NKT activity [14, 56, 57].

#### 6.1. Metabolic Diseases

NKT cells have been detected in high numbers in the liver and adipose tissue in mice, and due to their glycolipid reactivity, NKT cells have been associated with the development of non-alcoholic fatty liver disease (NAFLD), obesity-associated inflammation, and resistance to insulin [58]. In the pathogenesis of NAFLD, hepatic NKT cells have shown a dual role, being protective during the early phase of the disease while promoting pathological fibrogenesis in later stages of more severe NAFLD [59, 60]. In murine models of obesity fed with a diet high in fatty acids, hepatic and adipose NKT cells are rapidly activated and, consequently, promote tissue inflammation, insulin resistance, and hepatic steatosis [61]. On the other hand, the adoptive transfer of NKT cells into leptin-deficient murine leads to the reduction of fatty liver and glycemia [62]. Similarly, the adoptive transfer of NKT cells into murine fed with a low-fatty acid diet promotes insulin resistance, which does not occur when NKT cells are transferred
into animals fed with a diet high in fat [63]. Indeed, in CD1d and α18-null mice fed with a diet low in fat, a decrease in insulin resistance was observed [64].

6.2. Autoimmune Diseases. During murine autoimmune encephalomyelitis, the IFN-γ-producing NKT1 cells favor the pathogenic response of Th1 and Th17 lymphocytes in the central nervous system [65]. Conversely, IL-4-producing NKT2 cells inhibit the Th1 response, but not the pathogenic Th17 response [66, 67]. In a murine model of alopecia areata induced by scalp xenografts and inoculation of PBMCs stimulated in vitro with IL-2, an increase in the number of NKT1 cells was observed [68]. In turn, this increase in the NKT1 cell number led to the expansion of T helper and cytotoxic lymphocytes and an increment in the production of IFN-γ, causing hair follicle dystrophy and focal hair loss [68]. In different mice models of systemic lupus erythematosus, NKT cells have been associated with an increase in lupus nephritis and the appearance of severe skin lesions [14, 69, 70]. In SJL/J mice in which lupus was induced by inoculation of pristane (tetramethyl-pentadecane), the administration of α-GaLCer favored the expansion and activation of NKT cells with proinflammatory activity [69]. Indeed, the long-term administration of an IgG2a anti-NK1.1 monoclonal antibody ameliorated the lupus-like disease in NZB/W mice, demonstrating the pathological role of NKT cells [71]. In autoimmune hepatitis, an increased number of TNF-α-producing NKT cells was observed in the liver and peripheral blood, which were characterized by producing reduced levels of IFN-γ and the absence of IL-4 [72]. In this way, they contributed to exacerbate the pathological inflammation.

6.3. Bone Resorptive Diseases. During rheumatoid arthritis, NKT cells play a pathological role by promoting the progressive destruction of articular bone [14, 70]. In rheumatoid arthritis-affected patients, abundant infiltration of NKT1 cells has been observed in the affected joints [15]. Indeed, in an animal model of collagen-induced rheumatoid arthritis (CIA), long-term administration of α-GaLCer induced the activation of infiltrating NKT cells, which promoted the differentiation of T helper lymphocytes with proinflammatory activity [14]. Otherwise, in osteoporosis-affected patients, bone damage has been directly associated with the activity of NKT1 and NKT17 cells [17]. Indeed, NKT cells favor the increase of receptor activator of nuclear factor κB ligand (RANKL) expression levels, the key factor responsible for osteoclastogenesis and osteoclast-mediated bone resorption, a phenomenon that rises with the severity of the disease and depends on the loss of estrogens [17].

7. Pathologic Role of NKT1, NKT2, and NKT17 Cells during Periodontitis

Periodontitis results from polymicrobial synergy and dysbiosis of the bacterial communities colonizing the subgingival environment; however, periodontal tissue breakdown is mainly determined by the host’s immune response, where the T-lymphocyte subpopulations play a key role in the alveolar bone resorption that leads to tooth loss [73, 74]. Indeed, alveolar bone resorption involves the antagonistic relationship between the activity of RANKL-producing Th17 lymphocytes and IL-10-producing T regulatory (Treg) lymphocytes [75, 76]. Thus, alveolar bone resorption is, at least in part, a consequence of the Th17/Treg imbalance of the immune response deployed in the periodontitis-affected tissues, which causes the upregulation of RANKL, and other proinflammatory cytokines, that further promote osteoclastogenesis and alveolar bone loss [77–79].

Various in vivo and in vitro studies have established the pathogenic role of NKT cells during periodontitis [80]. In this context, Gram-negative bacteria contain glycosphingolipids in their outer membrane; thus, periodontal pathogenic bacteria, such as Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Tannerella forsythia, and Treponema denticola may express glycosphingolipids in their structure, which could be processed and presented by CD1d+ APCs and consequently activate NKT cells [81–83]. After oral inoculation of P. gingivalis and intraperitoneal administration of α-GaLCer in mice, NKT cells promoted systemic inflammation, periodontal RANKL production, osteoclastogenesis, and alveolar bone loss [84, 85]. Interestingly, when periodontitis was induced in CD1d−/− mice, oral inoculation of P. gingivalis triggered lesser alveolar bone resorption as compared with periodontitis induced in wildtype mice [84, 85]. When human-derived NKT cells were exposed in vitro to dendritic cells stimulated with A. actinomycetemcomitans, they secreted higher levels of IFN-α, IFN-β, and IFN-γ, in a dose-dependent manner, in comparison with NKT cells exposed to P. gingivalis-primed dendritic cells [86, 87]. These results detected in NKT cells confirm the greater immunogenic capacity of A. actinomycetemcomitans over P. gingivalis also described in other immune cells [88–90].

In periodontitis-affected tissues, T lymphocytes with invariant TCR Vα24/41aQ have been detected as the dominant clone among Vα24+ cells, and this cell population includes NKT cells [91]. In gingival biopsies obtained from periodontitis or gingivitis-affected patients, the expression of the marker Vα24 and the different isoforms of CD1 were analyzed, observing a predominance of CD1d over CD1a, CD1b, and CD1c isoforms and higher number of CD1d+ cells and Vα24+ NKT cells in periodontitis patients, as compared with gingivitis patients [83]. Although dendritic cells can express CD1d, the analysis of CD1d and CD83 double expression revealed a significant number of infiltrating CD1d+CD83+ cells in periodontal lesions, which do not correspond to dendritic cells [83]. This indicates that other APCs that share the CD1d molecule could be involved in the antigenic presentation and activation of NKT cells during periodontitis [42, 83]. Indeed, the co-expression of CD1d and CD19 on the same cells and proximate infiltration of CD1d+ and Vα24+ cells was observed in periodontitis-affected tissues, suggesting that CD1d+ B lymphocytes could activate Vα24+ NKT cells in a CD1d-restricted manner [83], being B lymphocytes largely present in the diseased gingival tissues infiltrate of periodontitis-affected patients [92]. Moreover, human NKT cells have
the capacity to recognize antigens presented by CD1d on B lymphocytes, and in turn, activated NKT cells can induce B-cell proliferation and immunoglobulin production [83, 93]. Thus, the pathogenic role of NKT cells during periodontitis could be tightly linked to the activity of B lymphocytes, both in their role as CD1d-restricted APCs and as antibody-producing effector cells.

Consistent evidence has demonstrated the central role of RANKL in bone homeostasis and pathological bone resorption [76]. Even so, RANKL has also been associated with other physiological processes, such as alveologenesis during the pregnancy-associated mammary gland development and thymic selection of immune cells to acquire the property of distinguishing self-antigens from non-self-antigens [94–96]. During thymic selection, NKT cells express RANKL in their membrane, which in turn interacts with the RANK receptor expressed in mTECs and leads to the activation of the transcription factor AIRE, the expression of MHC associated with tissue-specific antigens, and the promotion of apoptosis of the recipient cells [96–98]. To date, the presence of NKT cells that produce RANKL in the peripheral tissues has not been demonstrated; however, their existence would allow to hypothesize that RANKL-producing NKT cells could be associated with the immune control of bone loss during osteolytic diseases, including periodontitis.

Although these antecedents could allow us to establish a clear association between the activity of NKT cells and the pathological events that characterize periodontitis, to date, there is no clear evidence that supports the direct relationship of a particular NKT subset with the pathogenesis of the disease. The currently accepted paradigm that contributes to explain the pathogenesis of periodontitis involves an immuno-inflammatory response mediated by the activity
of Th1, Th2, Th17, and Treg lymphocytes, where Th1 and Th17 lymphocytes have been more related to the onset and progression of periodontitis, while Th2 and Treg lymphocytes have been more related to the suppression of the Th1 and Th17 responses, periodontitis remission, and periodontal healing [86, 99–105]. However, a functional relationship between Th1, Th2, or Th17 lymphocytes and NKT1, NKT2, or NKT17 cells during periodontitis has not been established yet. Given the similarity of their cytokine profile that justifies their names, it is plausible to hypothesize a functional relationship between the Th1/NKT1, Th2/NKT2, and Th17/NKT17 cells (Figure 5). In this sense, a periodontal protective relationship could also be observed between Treg lymphocytes and the recently described NKT10 cells, which produce IL-10 and fulfill regulatory activities [66, 67, 106, 107].

8. NKT10 Cells: A New NKT Subset with Regulatory Functions

Recently, a new subset of NKT cells with regulatory capacity characterized by their IL-10 production has been described, the reason they are termed NKT10 cells [5, 108]. The functional capacities of NKT10 are the subject of current research; even so, it has been clearly established that, after glycolipid antigenic stimulation, NKT10 cells reduce their capacity to produce proinflammatory cytokines and largely increase their IL-10 production [5, 108]. In this way, NKT10 cells are able to favor and enhance immunoregulatory responses by promoting the clonal expansion and activity of Treg lymphocytes and M2 macrophages [5, 108, 109]. Indeed, NKT10 cells express several common markers with Treg lymphocytes, including the surface markers CD152 (CTLA4), CD279 (PD1), and CD304 (Neuropilin-1) [5, 108]. In mice, NKT10 cells are located mainly in the thymus, spleen, and adipose tissue; in the latter, NKT10 cells correspond to ~15% of the activated NKT cells [108, 110], and in humans, 0.5% of the circulating blood cells are NKT10 cells [5, 108].

The regulatory potential attributed to IL-10-producing NKT10 cells has led to emerging proposals targeting them as a novel therapy for various inflammatory diseases, in such a way that NKT10 activation and expansion could favor a protective immune response [5, 108]. For instance, during autoimmune encephalomyelitis in mice, NKT10 cells inhibit the pathogenic activity of Th1 lymphocytes in the central nervous system [66, 67]. Similarly, in a murine model of alopecia areata, inoculation of IL-2-pulsed PBMCs previously exposed to NKT10 cells led to the inhibition of the generation of alopecic lesions, demonstrating the protective role of NKT10 cells in this disease [107]. In the same way, in an animal model of systemic lupus erythematosus, short-term stimulation with α-GalCer induced an increase in IL-10 production, which led to less secretion of autoantibodies and an increase in the production of tolerogenic cytokines [106]. Thus, NKT10 cells could fulfill a protective role in the pathogenesis of lupus erythematosus, related to their ability to regulate the production of autoreactive IgG by CD1δ+ B lymphocytes [106].

The inoculation of α-GalCer can promote the expansion of NKT10 cells and an anti-inflammatory environment mediated by the production of Th2 and Treg-related cytokines in diverse diseases [66, 108, 111]. In this sense, the activation of NKT10 cells favors the IL-10 mediated transactivation of Treg lymphocytes, and thus, the regulation of pathological responses [108]. To date, the regulatory role of NKT10 cells and their possible functional relationship with Treg lymphocytes during periodontitis has not been demonstrated yet, making the immuno-therapeutic proposal based on the induction of NKT10 cells by stimulation with α-GalCer or other glycolipid antigens to control periodontitis, in our opinion, attractive. In this way, the induction of NKT10 activity in infected periodontal tissues could lead to the transactivation of Treg lymphocytes, the promotion of phenotypic stability of Treg lymphocytes, and the recovery of the Th17/Treg balance.

9. Concluding Remarks

Multiple lines of evidence point to the pathogenic role of NKT cells in diverse inflammatory and osteolytic diseases. Similarly, consistent evidence has established that an increase in effector NKT cell activity promotes systemic inflammation, local RANKL production, and alveolar bone resorption during periodontitis. To date, there is no clear evidence that describes the pathogenic role of a specific NKT subset during periodontitis; however, the ability of NKT1 and NKT17 cells to produce proinflammatory cytokines, specifically IFN-γ and IL-17A, respectively, broadens the conceptual paradigm that allows us to understand the pathogenesis of periodontitis. In this context, the recent discovery of NKT10 cells with regulatory potential allows us the possibility of exploring a new therapeutic target with the potential to regulate the Th17/Treg imbalance that characterizes the disease. Thus, further studies are required to unravel the pathogenic role of NKT1 and NKT17 cells and the regulatory role of NKT10 cells during periodontitis.

Data Availability

No data were used to support this study.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

SM-R and RV conceived the review. SM-R, NID, MAP, LG-O, and AS-C were involved in drafting the manuscript. EAC, CR, and AMC critically evaluated and supplemented the manuscript. SM-R and JD-Z designed and prepared the Figures. RV revised and prepared the manuscript for submission. All the authors read and approved the final version of the article.
Funding

This study was financially supported by Agencia Nacional de Investigación y Desarrollo (ANID) from the Chilean Government [Fondecyt 1181780]. SM-R, EAC, and AS-C were the recipients of Ph.D. scholarships from the Faculty of Dentistry, Universidad de Chile, Chile. LG-O [Fondecyt 21190087] and CR [Fondecyt 21180841] were the recipients of Ph.D. scholarships from ANID.

References

[1] B. J. Fowlkes, A. M. Krusiebeck, H. Ton-That et al., “A novel population of T-cell receptor αβ-bearing thymocytes which predominantly expresses a single Vβ gene family,” Nature, vol. 329, no. 6136, pp. 251–254, 1987.
[2] A. Bendelac, O. Lantz, M. E. Quimby, J. W. Yewdell, J. R. Bennink, and R. R. Brutkiewicz, “CD1 recognition by mouse NK1+ T lymphocytes,” Science, vol. 268, no. 5212, pp. 863–865, 1995.
[3] K. Benlagha, A. Weiss, L. Teyton, and A. Bendelac, “In Vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers,” The Journal of Experimental Medicine, vol. 191, no. 11, pp. 1895–1904, 2000.
[4] A. Bendelac, “Mouse NK1+ T cells,” Current Opinion in Immunology, vol. 7, no. 3, pp. 367–374, 1995.
[5] G. Wingender, D. Sag, and M. Kronenberg, “NKT10 cells: A novel iNKT cell subset,” Oncotarget, vol. 6, no. 29, pp. 26552-26553, 2015.
[6] S. B. Bennstein, “Unraveling natural killer T-cells development,” Frontiers in Immunology, vol. 8, p. 1950, 2018.
[7] D. I. Godfrey, K. J. Hammond, L. D. Poulton, M. J. Smyth, and A. G. Baxter, “NKT cells: Facts, functions and fallacies,” Immunology Today, vol. 21, no. 11, pp. 573–583, 2000.
[8] A. Bendelac, P. B. Savage, and L. Teyton, “The biology of NKT cells,” Annual Review of Immunology, vol. 25, no. 1, pp. 297–336, 2007.
[9] C. J. Montoya, D. Pollard, J. Martinson et al., “Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11,” Immunology, vol. 122, no. 1, pp. 1–14, 2007.
[10] T. Ohteki and H. R. MacDonald, “Major histocompatibility complex class I related molecules control the development of CD4+8- and CD4-8- subsets of natural killer 1.1+ T cell receptor-αβ12 cells in the liver of mice,” The Journal of Experimental Medicine, vol. 180, no. 2, pp. 699–704, 1994.
[11] L. J. Carreño, N. A. Saavedra-Avila, and S. A. Porcelli, “Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents,” Clin Transl Immunology, vol. 5, no. 4, p. e69, 2016.
[12] Y. Wang, S. Sedimbi, L. Løfbom, A. K. Singh, S. A. Porcelli, and S. L. Cardell, “Unique invariant natural killer T cells promote intestinal polyps by suppressing Th1 immunity and promoting regulatory T cells,” Mucosal Immunology, vol. 11, no. 1, pp. 131–143, 2018.
[13] L. Wu and L. Van Kaer, “Natural killer T cells and autoimmune disease,” Current Molecular Medicine, vol. 9, no. 1, pp. 4–14, 2009.
[14] C. Rizzo, L. La Barbera, M. Lo Pizzo, F. Ciccia, G. Sireci, and G. Guggino, “Invariant NKT cells and rheumatic disease: Focus on primary Sjogren syndrome,” International Journal of Molecular Sciences, vol. 20, no. 21, p. 5435, 2019.
[15] D. Gutowska-Owsiai, M. A. Birchall, R. J. Moots, S. E. Christmas, and L. Pazmany, “Proliferatory defect of invariant population and accumulation of non-invariant CD1d-restricted natural killer T cells in the joints of RA patients,” Modern Rheumatology, vol. 24, no. 3, pp. 434–442, 2014.
[16] C. M. Crosby and M. Kronenberg, “Tissue-specific functions of invariant natural killer T cells,” Nature Reviews Immunology, vol. 18, no. 9, pp. 559–574, 2018.
[17] K. Tilkieridis, G. Kiziridis, A. Ververidis et al., “Immunoprophylaxis: A new role for invariant natural killer T (NKT) cells through overexpression of nuclear factor-xB ligand (RANKL),” Medical Science Monitor, vol. 25, pp. 2151–2158, 2019.
[18] C. M. Liao, M. I. Zimmer, S. Shannuganad, H.-T. Yu, S. L. Cardell, and C.-R. Wang, “Disregulation of CD1d-restricted type II natural killer T cells leads to spontaneous development of colitis in mice,” Gastroenterology, vol. 142, no. 2, pp. 326–334, 2012.
[19] D. I. Kwon and Y. J. Lee, “Lineage differentiation program of invariant natural killer T cells,” Immune Network, vol. 17, no. 6, pp. 365–377, 2017.
[20] K. Hogquist and H. Georgiev, “Recent advances in iNKT cell development,” F1000Research, vol. 9, pp. 1–10, 2020.
[21] E. E. Gray, S. Friend, K. Suzuki, T. G. Phan, and J. G. Cyster, “Subcapsular sinus macrophage fragmentation and CD169+ MΦ acquisition by closely associated IL-17-committed innate-like lymphocytes,” PLoS One, vol. 7, no. 6, e38258, 2012.
[22] Y. J. Lee, G. J. Starrett, S. T. Lee et al., “Lineage-specific effector signatures of invariant NKT cells are shared amongst γδ T, innate lymphoid, and Th cells,” The Journal of Immunology, vol. 197, no. 4, pp. 1460–1470, 2016.
[23] H. Georgiev, I. Ravens, C. Benarafa, R. Forster, and G. Bernhardt, “Distinct gene expression patterns correlate with developmental and functional traits of iNKT subsets,” Nature Communications, vol. 7, no. 1, p. 13116, 2016.
[24] S. Harsha Krovi, J. Zhang, M. J. Michaels-Foster et al., “Thymic iNKT single cell analyses unmask the common developmental program of mouse innate T cells,” Nature Communications, vol. 11, no. 1, p. 6238, 2020.
[25] Y. J. Lee, S. C. Jameson, and K. A. Hogquist, “Alternative memory in the CD8+ T cell lineage,” Trends in Immunology, vol. 32, no. 2, pp. 50–56, 2011.
[26] P. T. Lee, K. Benlagha, L. Teyton, and A. Bendelac, “Distinct functional lineages of human Vα24 natural killer T cells,” The Journal of Experimental Medicine, vol. 195, no. 5, pp. 637–641, 2002.
[27] T. Yamashita, R. Wada, T. Sasaki et al., “A vital role for glycosphingolipid synthesis during development and differentiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 16, pp. 9142–9147, 1999.
[28] M. Tsuji, “Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands,” Cellular and Molecular Life Sciences, vol. 63, no. 16, pp. 1889–1898, 2006.
[29] A. H. Merrill Jr., “Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics,” Chemical Reviews, vol. 111, no. 10, pp. 6387–6422, 2011.
[30] J. L. Amprey, J. S. Im, S. J. Turco et al., "A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan," The Journal of Experimental Medicine, vol. 200, no. 7, pp. 895–904, 2004.

[31] V. Siriram, W. Du, J. Gervay-Hague, and R. R. Brutkiewicz, "Cell wall glycosphingolipids of Sphingomonas paucimobilis-sare CD1d-specific ligands for NK T cells," European Journal of Immunology, vol. 35, no. 6, pp. 1692–1701, 2005.

[32] Y. Kinjo, E. Tupin, D. Wu et al., "Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria," Nature Immunology, vol. 7, no. 9, pp. 978–986, 2006.

[33] Y. J. Chang, H. Y. Kim, L. A. Albacker et al., "Influenza infection in suckling mice expands an NK T cell subset that protects against airway hyperreactivity," The Journal of Clinical Investigation, vol. 121, no. 1, pp. 57–69, 2011.

[34] Y. Kinjo, P. Illarionov, J. L. Vela et al., "Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria," Nature Immunology, vol. 12, no. 10, pp. 966–974, 2011.

[35] D. C. Barral and M. B. Brenner, "CD1 antigen presentation: how it works," Nature Reviews Immunology, vol. 7, no. 12, pp. 929–941, 2007.

[36] S. Freitag, E. Landais, V. Zadorozhny et al., "Scavenger receptors target glycolipids for natural killer T cell activation," The Journal of Clinical Investigation, vol. 122, no. 11, pp. 3943–3954, 2012.

[37] B. Pei, J. L. Vela, D. Zajonc, and M. Kronenberg, "Interplay between carbohydrate and lipid in recognition of glycolipid antigens by natural killer T cells," Annals of the New York Academy of Sciences, vol. 1253, no. 1, pp. 68–79, 2012.

[38] M. Bihurger and G. Tieg, "α-galactosylceramide-induced liver injury in mice is mediated by TNF-α but independent of Kupffer cells," The Journal of Immunology, vol. 175, no. 3, pp. 1540–1550, 2005.

[39] E. J. Adams and J. Lopez-Sagasta, "The immutable recognition of CD1d," Immunity, vol. 34, no. 3, pp. 281–283, 2011.

[40] T. Kawano, J. Cui, Y. Koezu et al., "CD1d-restricted and TCR-mediated activation of VA14 NK T cells by glycosylcera-mides," Science, vol. 278, no. 5343, pp. 1626–1629, 1997.

[41] J. E. Gumperz, C. Roy, A. Makowska et al., "Murine CD1d-restricted T cell recognition of cellular lipids," Immunity, vol. 12, no. 2, pp. 211–221, 2000.

[42] R. S. Blumberg, C. Terhorst, P. Bleicher et al., "Expression of a nonpolymorphic MHC class I-like molecule, CD1d, by human intestinal epithelial cells," The Journal of Immunology, vol. 147, no. 8, pp. 2518–2524, 1991.

[43] L. Wu, C. L. Gabriel, V. V. Parekh, and L. Van Kaer, "Invariant natural killer T cells: Innate-like T cells with potent immunomodulatory activities," Tissue Antigens, vol. 73, no. 6, pp. 535–545, 2009.

[44] Y. J. Lee, H. Wang, G. J. Starrett, V. Phuong, S. C. Jameson, and K. A. Hogquist, "Tissue-specific distribution of iNKT cells impacts their cytokine response," Immunity, vol. 43, no. 3, pp. 566–578, 2015.

[45] S. P. Berzins, F. W. McNab, C. M. Jones, M. J. Smyth, and D. I. Godfrey, "Long-term retention of mature NK1.1 T NKT cells in the thymus," The Journal of Immunology, vol. 176, no. 7, pp. 4059–4065, 2006.

[46] M. B. Drennan, A. S. Franki, P. Dewint et al., "Cutting edge: The chemokine receptor CXCR3 retains invariant NK T cells in the thymus," The Journal of Immunology, vol. 183, no. 4, pp. 2213–2216, 2009.

[47] B. Lucas, A. J. White, E. J. Cosway et al., "Diversity in medullary thymic epithelial cells controls the activity and availability of iNKT cells," Nature Communications, vol. 11, no. 1, p. 2198, 2020.

[48] S. C. Shissler, N. J. Singh, and T. J. Webb, "Thymic resident NKT cell subsets show differential requirements for CD28 co-stimulation during antigenic activation," Scientific Reports, vol. 10, no. 1, p. 8218, 2020.

[49] M. F. Krummel and J. P. Allison, "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation," The Journal of Experimental Medicine, vol. 182, no. 2, pp. 459–465, 1995.

[50] D. I. Godfrey and M. Kronenberg, "Going both ways: Immune regulation via CD1d-dependent NKT cells," The Journal of Clinical Investigation, vol. 114, no. 10, pp. 1379–1388, 2004.

[51] S. J. Kang and P. Cresswell, "Saposins facilitate CD1d-restricted presentation of an exogenous lipid antigen to T cells," Nature Immunology, vol. 5, no. 2, pp. 175–181, 2004.

[52] M. Kronenberg and L. Gapin, "The unconventional lifestyle of NKT cells," Nature Reviews Immunology, vol. 2, no. 8, pp. 557–568, 2002.

[53] D. Artis and H. Spits, "The biology of innate lymphoid cells," Nature, vol. 517, no. 7534, pp. 293–301, 2015.

[54] D. Nau, N. Altmaier, and J. Mattner, "Mechanisms of innate lymphoid cell and natural killer T cell activation during mucosal inflammation," Journal of Immunology Research, vol. 2014, p. 546596, 2014.

[55] J. Saez de Guinoa, R. Jimeno, N. Farhadi et al., "CD1d-mediated activation of group 3 innate lymphoid cells drives IL-22 production," EMBO Reports, vol. 18, no. 1, pp. 39–47, 2017.

[56] M. B. Drennan, S. Aspeslagh, and D. Elewaut, "Invariant natural killer T cells in rheumatic disease: A joint dilemma," Nature Reviews Rheumatology, vol. 6, no. 2, pp. 90–98, 2010.

[57] L. Van Kaer, V. V. Parekh, and L. Wu, "Invariant NK T cells: Potential for immunotherapeutic targeting with glycolipid antigens," Immunotherapy, vol. 3, no. 1, pp. 59–75, 2011.

[58] L. Wu and L. Van Kaer, "Contribution of lipid-reactive natural killer T cells to obesity-associated inflammation and insulin resistance," Adipocytes, vol. 2, no. 1, pp. 12–16, 2013.

[59] K. Tajiri and Y. Shimizu, "Role of NKT cells in the pathogenesis of NAFLD," International Journal of Hepatology, vol. 2012, p. 850836, 2012.

[60] L. Van Kaer, V. V. Parekh, and L. Wu, "Invariant natural killer T cells as sensors and managers of inflammation," Trends in Immunology, vol. 34, no. 2, pp. 50–58, 2013.

[61] L. Wu, V. V. Parekh, C. L. Gabriel et al., "Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 19, pp. E1143– E1152, 2012.

[62] E. Elinav, O. Pappo, M. Sklar-Levy et al., "Adaptive transfer of regulatory NK T lymphocytes ameliorates non-alcoholic steatohepatitis and glucose intolerance in Ob/Ob mice and is associated with intrahepatic CD8 trapping," The Journal of Pathology, vol. 209, no. 1, pp. 121–128, 2006.

[63] X. Ma, J. Hua, and Z. Li, "Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing..."
hepatic NKT cells,” *Journal of Hepatology*, vol. 49, no. 5, pp. 821–830, 2008.

[64] H. S. Schipper, M. Rakshandehroo, S. F. van de Graaf et al., “Natural killer T cells in adipose tissue prevent insulin resistance,” *The Journal of Clinical Investigation*, vol. 122, no. 9, pp. 3343–3354, 2012.

[65] S. J. Oh and D. H. Chung, “Invariant NKT cells producing IL-4 or IL-10, but not IFN-γ, inhibit the Th1 response in experimental autoimmune encephalomyelitis, whereas none of these cells inhibits the Th17 response,” *The Journal of Immunology*, vol. 186, no. 12, pp. 6815–6821, 2011.

[66] A. K. Singh, M. T. Wilson, S. Hong et al., “Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis,” *The Journal of Experimental Medicine*, vol. 194, no. 12, pp. 1801–1811, 2001.

[67] L. T. Mars, V. Laloux, K. Goude et al., “Cutting edge: Va14-Ja281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice,” *The Journal of Immunology*, vol. 168, no. 12, pp. 6007–6011, 2002.

[68] A. Gilhar, A. G. Schrum, A. Etzioni, H. Waldmann, and R. Paus, “Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies,” *Autoimmunity Reviews*, vol. 15, no. 7, pp. 726–735, 2016.

[69] O. T. Chan, V. Patilwal, J. M. McNiff, S. H. Park, A. Bendelac, and M. J. Shlomchik, “Deficiency in β2-microglobulin, but not CD1d, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Fas<sup>−/−</sup> Mice: An example of disease regulation at the organ level,” *The Journal of Immunology*, vol. 167, no. 5, pp. 2985–2990, 2001.

[70] A. Chiba, S. Oki, K. Miyamoto, H. Hashimoto, T. Yamamura, and S. Miyake, “Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-1-truncated analog of α-galactosylceramide,” *Arthritis and Rheumatism*, vol. 50, no. 1, pp. 305–313, 2004.

[71] E. Postól, A. Meyer, F. Cardillo et al., “Long-term administration of IgG2a anti-NK1.1 monoclonal antibody ameliorates lupus-like disease in NZB/WB mice in spite of an early worsening induced by an IgG2a-dependent BAFF/BlyS production,” *Immunochemistry*, vol. 125, no. 2, pp. 184–196, 2008.

[72] M. Sebode, J. Wigger, P. Filippe et al., “Inflammatory phenotype of intrahepatic sulfatide-reactive type II NKT cells in humans with autoimmune hepatitis,” *Frontiers in Immunology*, vol. 10, p. 1065, 2019.

[73] G. Hajishengallis and J. M. Korostoff, “Revisiting the Page & Schroeder model: The good, the bad and the unknowns in the periodontal host response 40 years later,” *Periodontology 2000*, vol. 75, no. 1, pp. 116–151, 2017.

[74] R. J. Lamont, H. Koo, and G. Hajishengallis, “The oral microbiota: Dynamic communities and host interactions,” *Nature Reviews Microbiology*, vol. 16, no. 12, pp. 745–759, 2018.

[75] G. P. Garlett and W. V. Giannobile, “Macrophages: The bridge between inflammation resolution and tissue repair,” *Journal of Dental Research*, vol. 97, no. 10, pp. 1079–1081, 2018.

[76] C. Alvarez, G. Monasterio, F. Cavalla et al., “Osteoimmunology of oral and maxillofacial diseases: Translational applications based on biological mechanisms,” *Frontiers in Immunology*, vol. 10, p. 1664, 2019.

[77] C. Alvarez, C. Rojas, L. Rojas, E. A. Cafferata, G. Monasterio, and R. Vernal, “Regulatory T lymphocytes in periodontitis: A translational view,” *Mediators of Inflammation*, vol. 2018, p. 7806912, 2018.

[78] C. Alvarez, S. Suliman, R. Almarhouni et al., “Regulatory T cell phenotype and anti-osteoclastogenic function in experimental periodontitis,” *Scientific Reports*, vol. 10, no. 1, p. 19018, 2020.

[79] F. Cavalla, A. Letra, R. M. Silva, and G. P. Garlet, “Determinants of periodontal/periapical lesion stability and progression,” *Journal of Dental Research*, p. 22034529052341, 2020.

[80] A. Seidel, C. L. Seidel, M. Weider, R. Junker, L. Gözl, and H. Schmetzer, “Influence of natural killer cells and natural killer T cells on periodontal disease: A systematic review of the current literature,” *International Journal of Molecular Sciences*, vol. 21, no. 4, p. 9766, 2020.

[81] Y. Kinjo, D. Wu, G. Kim et al., “Recognition of bacterial glycosphingolipids by natural killer T cells,” *Nature*, vol. 434, no. 7032, pp. 520–525, 2005.

[82] J. Mattner, K. L. DelBord, N. Ismail et al., “Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections,” *Nature*, vol. 434, no. 7032, pp. 525–529, 2005.

[83] R. Amanuma, T. Nakajima, H. Yoshie, and K. Yamazaki, “Increased infiltration of CD1d<sup>+</sup> and natural killer T cells in periodontal disease tissues,” *Journal of Periodontal Research*, vol. 41, no. 1, pp. 73–79, 2006.

[84] M. Hu, J. H. Bassett, L. Danks et al., “Activated invariant NKT cells regulate osteoclast development and function,” *The Journal of Immunology*, vol. 186, no. 5, pp. 2910–2917, 2011.

[85] Y. Aoki-Nonaka, T. Nakajima, S. Miyauchi et al., “Natural killer T cells mediate alveolar bone resorption and a systemic inflammatory response in response to oral infection of mice with *Porphyromonas gingivalis*,” *Journal of Periodontal Research*, vol. 49, no. 1, pp. 69–76, 2014.

[86] G. P. Garlett, “Destructive and protective roles of cytokines in periodontitis: A re-appraisal from host defense and tissue destruction viewpoints,” *Journal of Dental Research*, vol. 89, no. 12, pp. 1349–1363, 2010.

[87] M. Nowak, B. Krämer, M. Haupt et al., “Activation of invariant NK T cells in periodontitis lesions,” *The Journal of Immunology*, vol. 190, no. 5, pp. 2282–2291, 2013.

[88] R. Vernal, J. Diaz-Zúñiga, S. Melgar-Rodríguez et al., “Activation of RANKL-induced osteoclasts and memory T lymphocytes by *Porphyromonas gingivalis* is serotype dependant,” *Journal of Clinical Periodontology*, vol. 41, no. 5, pp. 451–459, 2014.

[89] J. Diaz-Zúñiga, G. Monasterio, C. Alvarez et al., “Variability of the dendritic cell response triggered by different serotypes of *Aggregatibacter actinomycetemcomitans* or *Porphyromonas gingivalis* is toll-like receptor 2 (TLR2) or TLR4 dependent,” *Journal of Clinical Periodontology*, vol. 41, no. 5, pp. 451–459, 2014.
Mediators of Inflammation

[92] Y. Gu and X. Han, "Toll-like receptor signaling and immune regulatory lymphocytes in periodontal disease," *International Journal of Molecular Sciences*, vol. 21, no. 9, p. 3329, 2020.

[93] G. Galli, S. Nuti, S. Tavarini et al., "CD1d-restricted help to B cells by human invariant natural killer T lymphocytes," *The Journal of Experimental Medicine*, vol. 197, no. 8, pp. 1051–1057, 2003.

[94] N. S. Kim, H. T. Kim, M. C. Kwon et al., "Survival and differentiation of mammary epithelial cells in mammary gland development require nuclear retention of Id2 due to RANK signaling," *Molecular and Cellular Biology*, vol. 31, no. 23, pp. 4775–4788, 2011.

[95] C. Sobacchi, C. Menale, and A. Villa, "The RANKL-RANK axis: A bone to thymus round trip," *Frontiers in Immunology*, vol. 10, p. 629, 2019.

[96] T. Ono, M. Hayashi, F. Sasaki, and T. Nakashima, "RANKL signaling: Bone metabolism, the immune system, and beyond," *Inflammation and Regeneration*, vol. 40, no. 1, p. 2, 2020.

[97] S. W. Rossi, M. Y. Kim, A. Leibbrandt et al., "RANK signals from CD4+3′ inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla," *The Journal of Experimental Medicine*, vol. 204, no. 6, pp. 1267–1272, 2007.

[98] A. J. White, W. E. Jenkinson, J. E. Cowan et al., "An essential role for medullary thymic epithelial cells during the intrathymic development of invariant NKT cells," *The Journal of Immunology*, vol. 192, no. 6, pp. 2659–2666, 2014.

[99] S. L. Gaffen and M. Hajishengallis, "A new inflammatory cytokine on the block: Re-thinking periodontal disease and the Th1/Th2 paradigm in the context of Th17 cells and IL-17," *Journal of Dental Research*, vol. 87, no. 9, pp. 817–828, 2008.

[100] N. Dutzan, J. Gamonal, A. Silva, M. Sanz, and R. Vernal, "Over-expression of forkhead box P3 and its association with receptor activator of nuclear factor-κB ligand, interleukin (IL)-17, IL-10 and transforming growth factor-β during the progression of chronic periodontitis," *Journal of Clinical Periodontology*, vol. 36, no. 5, pp. 396–403, 2009.

[101] G. P. Garlet, C. R. Cardoso, F. S. Mariano et al., "Regulatory T cells attenuate experimental periodontitis progression in mice," *Journal of Clinical Periodontology*, vol. 37, no. 7, pp. 591–600, 2010.

[102] D. T. Graves, T. Oates, and G. P. Garlet, "Review of osteoimmunology and the host response in endodontic and periodontal lesions," *Journal of Oral Microbiology*, vol. 3, no. 1, pp. 1–15, 2011.

[103] M. Hernández, N. Dutzan, J. García-Senich et al., "Host-pathogen interactions in progressive chronic periodontitis," *Journal of Dental Research*, vol. 90, no. 10, pp. 1164–1170, 2011.

[104] N. Dutzan, T. Kajikawa, L. Abusleme et al., "A dysbiotic microbiome triggers Th17 cells to mediate oral mucosal immunopathology in mice and humans," *Science Translational Medicine*, vol. 10, no. 463, p. eaat0797, 2018.

[105] N. M. Moutsopoulos and H. M. Moutsopoulos, "The oral mucosa: A barrier site participating in tissue-specific and systemic immunity," *Oral Diseases*, vol. 24, no. 1-2, pp. 22–25, 2018.

[106] J. Q. Yang, P. J. Kim, and R. R. Singh, "Brief treatment with iNKT cell ligand α-galactosylceramide confers a long-term protection against lupus," *Journal of Clinical Immunology*, vol. 32, no. 1, pp. 106–113, 2012.

[107] A. Ghraieb, A. Keren, A. Ginzburg et al., "iNKT cells ameliorate human autoimmunity: Lessons from alopecia areata," *Journal of Autoimmunity*, vol. 91, pp. 61–72, 2018.

[108] D. Sag, P. Krause, C. C. Hedrick, M. Kronenberg, and G. Wingender, "IL-10-producing NKT10 cells are a distinct regulatory invariant NKT cell subset," *The Journal of Clinical Investigation*, vol. 124, no. 9, pp. 3725–3740, 2014.

[109] L. Lynch, X. Michelet, S. Zhang et al., "Regulatory iNKT cells lack expression of the transcription factor PLZF and control the homeostasis of Treg cells and macrophages in adipose tissue," *Nature Immunology*, vol. 16, no. 1, pp. 85–95, 2015.

[110] G. Wingender, A. M. Birkholz, D. Sag et al., "Selective conditions are required for the induction of invariant NKT cell hyporesponsiveness by antigenic stimulation," *The Journal of Immunology*, vol. 195, no. 8, pp. 3838–3848, 2015.

[111] N. Burdin, L. Brossay, and M. Kronenberg, "Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis," *European Journal of Immunology*, vol. 29, no. 6, pp. 2014–2025, 1999.